Taipei VGH Practice Guidelines: Oncology Guidelines Index

Small Intestine (Duodenal cancer ; Ampulla of Vater cancer) Version 2022.11.03 Table of Content Staging, Manuscript



Taipei Veterans General Hospital Practices Guidelines for

Small Intestine

(Duodenal cancer ; Ampulla of Vater cancer)

2014年06月10日制定 2022年11月03日第七次修定

Table of Content

- Multidisciplinary Team
- Taipei VGH Periampullary Cancer Panel Members
- Pretreatment Work-ups
- TNM Staging (AJCC 8th ed)
- Histology Grade
- Resectable
- Post-operative Adjuvant Treatment
- Locally Advanced, Unresectable
- Metastatic Disease
- Recurrence After Resection
- References

Taipei VGH Practice
Guidelines:
Oncology Guidelines Index

Version 2022.11.03 Table of Content Staging, Manuscript

Multidisciplinary Team

- Surgical Oncologists specialized in Periampullary Cancer
- Gastroenterologists
- Medical Oncologists
- Radiation Oncologists
- Pathologists
- Diagnostic Radiologists
- Hospice Specialists
- Pharmacists
- Nurses (for specialized)
- Social Workers
- Dietitians (for Nutrition Support)

Taipei VGH Periampullary Cancer Panel Members

- Surgical Oncologist
 - 石宜銘*;王心儀*;陳世欽*;石柏威*
- Gastroenterologist

李重賓*;李沛璋*;王彦博*;李懿宬*;張天恩*;李癸训*;李偉平

- Endocrinologist
- 林亮羽*
- Medical Oncologist ^{趙毅*};陳明晃*;洪逸平*
- Radiation Oncologist 賴宜君*;吳元宏*;藍耿立
- Diagnostic Radiologist
 邱乃祈*;陳蓉宣*;柳建安
- Nuclear Medicine Specialist 林可瀚*
- Pathologist 楊清越*
- Pharmacist

胡晉嘉*

Taipei VGH Practice
Guidelines:
Oncology Guidelines Index

Version 2022.11.03 Table of Content Staging, Manuscript

Pretreatment work-ups

- History and physical exam
- CBC, platelets, chemistry profile and PT/APTT
- Abdominal CT with IV contrast
- Chest imaging
- Tumor markers: CEA, CA19-9
- Biopsy confirmation
- Optional studies
 - EUS
 - Endoscopic retrograde cholangiopancreatography (ERCP)
 - MRI/MRCP
 - Whole body bone scan
 - Upper GI panendoscopy
 - PET/CT scan
 - Cardiac function (cardiac ultrasound and/or ejection fraction + wall motion)
 - Pulmonary function test (if age > 65 and prepare for surgery)
 - Consider genetic testing for inherited mutations

• ATM, BRCA1, BRCA2, CDKN2A, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, and TP53 (patients with positive pathogenic mutation/family history of pancreatic/ampullary cancer) NCCN V1.2022-March 9, 2022

٠

Small Intestine (Duodenal cancer ; Ampulla of Vater cancer)

Duodenal cancer TNM Staging System: UICC/AJCC 2017 8th Edition

٠

Primary Tumor (T)

TX: Primary tumor cannot be assessed

- T0: No evidence of primary tumor
- Tis: Carcinoma in situ
- T1a: Tumor invades lamina propria
- T1b: Tumor invades submucosa
- T2: Tumor invades muscularis propria
- T3: Tumor invades through the muscularis propria into the subserosa or into the nonperitonealized perimuscular tissue (mesentery or retroperitoneum) without serosal penetration
- T4: Tumor perforates the visceral peritoneum or directly invades other organs or structures (includes other loops of small intestine, mesentery, and abdominal wall by way of serosa; for duodenum only, invasion of pancreas or bile duct)

- Regional lymph nodes (N)
 NX: Regional lymph nodes cannot be assessed
 N0: No regional lymph node metastasis
 N1: Regional lymph node metastasis (1-2)
 N2: Regional lymph node metastasis (> 2)
- Distant metastasis (M) M0: No distant metastasis M1: Distant metastasis

General Notes:

- **m** suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.
- **y** prefix indicates those cases in which classification is performed during or following initial multimodality therapy.
- r prefix indicates a recurrent tumor when staged after a disease-free interval, and is identified by the "r" prefix: rTNM.
- a prefix designates the stage determined at autopsy: aTNM. 6

Small Intestine

(Duodenal cancer ; Ampulla of Vater cancer)

Duodenal cancer

TNM Staging System: UICC/AJCC 2017 (8th Edition)

ANA	TOMIC STAGE/PI	ROGNOSTIC GRC	OUPS
Stage 0	Tis	NO	M0
Stage I	T1	NO	M0
	T2	NO	M0
Stage IIA	Т3	NO	M0
Stage IIB	Τ4	NO	M0
Stage IIIA	Any T	N1	M0
Stage IIIB	Any T	N2	M0
Stage IV	Any T	Any N	M1

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, 8th Edition (2017) published by Springer-Verlag New York. (For more information, visit http://www.cancerstaging.net) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer-Verlag New York, Inc., on behalf of the AJCC.

٠

Small Intestine (Duodenal cancer ; Ampulla of Vater cancer)

Ampulla of Vater cancer TNM Staging System: UICC/AJCC 2017 8th Edition

Primary Tumor (T)

TX: Primary tumor cannot be assessed

- T0: No evidence of primary tumor
- Tis: Carcinoma in situ
- T1a: Tumor limited to ampulla of Vater or sphincter of Oddi
- **T1b:** Tumor invades beyond the sphincter of Oddi or into the duodenal subucosa
- T2: Tumor invades into the muscularis propria of the duodenum
- T3a: Tumor invades pancreas (up to 0.5 cm)
- T3b: Tumor invades pancreas (more than 0.5 cm)
- **T4:** Tumor invades celiac axis, SMA, or common hepatic artery

• Regional lymph nodes (N)

NX: Regional lymph nodes cannot be assessed
N0: No regional lymph node metastasis
N1: Regional lymph node metastasis (1-3)
N2: Regional lymph node metastasis (> 3)

Distant metastasis (M) M0: No distant metastasis M1: Distant metastasis

General Notes:

m suffix indicates the presence of multiple primary tumors in

a single site and is recorded in parentheses: pT(m)NM.

- **y** prefix indicates those cases in which classification is performed during or following initial multimodality therapy.
- r prefix indicates a recurrent tumor when staged after a disease-free interval, and is identified by the "r" prefix: rTNM.
- a prefix designates the stage determined at autopsy:

Taipei VGH Practice Guidelines: Oncology Guidelines Index Small Intestine

(Duodenal cancer ; Ampulla of Vater cancer)

Ampulla of Vater cancer TNM Staging System: UICC/AJCC 2017 (8th Edition)

ANA	FOMIC STAGE/P	ROGNOSTIC GR	OUPS
Stage 0	Tis	NO	M0
Stage IA	T1a	NO	MO
Stage 1B	T1b	NO	M0
	Т2	NO	M0
Stage IIA	ТЗа	NO	M0
Stage IIB	T3b	NO	M0
Stage IIIA	T1a – T3b	N1	M0
Stage IIIB	Т4	Any N	M0
	Any T	N2	M0
Stage IV	Any T	Any N	M1

Histological feature

- **GX** Grade cannot be assessed
- **G1** Well differentiated
- **G2** Moderately differentiated
- **G3** Poorly differentiated
- **G4** Undifferentiated

High Risk Features in stage II duodenal cancer

Histological feature

G3 Poorly differentiated

G4 Undifferentiated


Resection margin

Lymph node status


<5 lymph nodes examined

Tumor perforation

Lympho-vascular or perineural invasion




- General -- FOLFOXIRI replaced with FOLFIRINOX
- Universal MMR or MSI testing is highly suggested in all newly diagnosed patients with SBA



High-risk features in stage II SBA include :

- Close or positive resection margins,
 - Consider sequential chemoradiation with capecitabine or infusional 5-FU if positive margin
- <5 lymph nodes examined if duodenal location or <8 lymph nodes examined if jejunal/ileal primary tumor location
- Tumor perforation.



Taipei VGH Practice Guidelines: Oncology Guidelines Index	(Duodenal ca	Small Intestine ncer ; Ampulla of Vater cance	er)	Version 2022.11.03 Table of Content <u>Staging, Manuscript</u>
NCCN NCCN Network®		Version 1.2022	,	
PATIENT STATUS	PRINCIPLES OF SYS	TEMIC THERAPY FOR ADVANCED INITIAL THERAPY		ATIC DISEASE ^{a,b} JENT THERAPY ⁱ
Patient with prior oxaliplatin exposure in the adjuvant setting or contraindication		FOLFIRI ± bevacizumab ^e or Taxane-based chemotherapy or ([Nivolumab ± ipilimumab] or pembrolizumab) ^{g,h} or dostarlimab-gxly ^{g,h} (dMMR/MSI-H only) —See Initial Therapy ◄	→ Best supp	ortive care

High Risk Features in ampulla vater cancer

Histological feature

G3 Poorly differentiated

G4 Undifferentiated

Resection margin

R1 or R2 resection

TNM stage: ≥T2

Lymph node status

Any positive lymph node

<5 lymph nodes examined


Tumor perforation

Lympho-vascular or perineural invasion

Histological type


Pancreato-biliary (CDX-negative, MUC1-positive)

Intestinal (CDX-positive, MUC1-negative)




Genetic counseling(*ATM*, *BRCA1*, *BRCA2*, *CDKN2A*, *MLH1*, *MSH2*, *MSH6*, *PALB2*, *PMS2*, *STK11*, and *TP53*) is recommended:

- Patients who test positive for a pathogenic mutation
- Patients with a positive family history of cancer, especially pancreatic/ampullary cancer, regardless of mutation status.



High-risk features:

imaging findings, markedly elevated CA 199, markedly elevated carcinoembryonic antigen (CEA), large primary tumors, large regional lymph nodes, excessive weight loss, and extreme pain.




- Stage I with high-risk feature: consider systemic therapy
 - See page 16
- Initiation of adjuvant systemic therapy is recommended within 12 weeks of surgery if the patient is medically fit.
- The optimal duration of treatment is 4 to 6 months.

Taipei VGH Practice Guidelines: Oncology Guidelines Index	Small Intestine (Duodenal cancer ; Ampulla of Vater cancer)	Version 2022.11.03 Table of Content Staging, Manuscript
NCCN Cancer A Network®	NCCN Guidelines Version 1.2022 Ampullary Adenocarcinoma	
disease doned • Molect profilin tumor	Good PS ⁿ Good PS ⁿ Good PS ⁿ Palliative indications ic g for ted ons, if eviously ular ng of tissue, if eviously	Disease progression <u>See AMP-7</u>

Good PS is defined as :

- ECOG 0–1
- Good biliary drainage
- Adequate nutritional intake



Good PS: Defined as ECOG 0–1, with good biliary drainage and adequate nutritional intake.

Consider specifically testing for potentially actionable somatic findings including, but not limited to:

- Fusions (ALK, NRG1, NTRK, ROS1, FGFR2, RET), mutations (BRAF, BRCA1/2, KRAS, PALB2)
- Amplifications (HER2)
- Microsatellite instability (MSI) and/or mismatch repair (MMR) deficiency.

Taipei VGH Practice	
Guidelines:	
Oncology Guidelines Index	

National NCCN Cancer Network[®]

Comprehensive NCCN Guidelines Version 1.2022 **Ampullary Adenocarcinoma**

PRINCIPLES OF SYSTEMIC THERAPY

Metastatic Disease (First-Line Therapy)

• Patients who progress with metastatic disease are not candidates for radiation unless required for palliative purposes.

Good PS ^f	Pancreatobiliary/Mixed Type • FOLFIRINOX ^a or modified FOLFIRINOX ^{a,g,7} • Gemcitabine + albumin-bound paclitaxel ⁸ • Gemcitabine + cisplatin ⁵ • Gemcitabine + capecitabine • FOLFOX	Intestinal Type • FOLFOXIRI ± bevacizumab ^h • FOLFOX ± bevacizumab ^h • FOLFIRI ± bevacizumab ^h • CapeOx ± bevacizumab ^h	Useful in Certain Circumstances • Pembrolizumab ^j (if MSI-H, dMMR or TMB-H [≥10 mut/Mb]) • Nivolumab + ipilimumab ^j (if MSI-H or dMMR, for intestinal type only)
Poor PS	 Gemcitabine Capecitabine 5-FU + leucovorin For select patients with ECOG 2 consider multi-agent regimensⁱ: FOLFOX Gemcitabine + albumin-bound paclitaxel 	 5-FU + leucovorin For select patients with ECOG 2 consider multi-agent regimensⁱ: FOLFOX ± bevacizumab^h FOLFIRI ± bevacizumab^h 5-FU ± bevacizumab^h Capecitabine ± bevacizumab^h CapeOx ± bevacizumab^h 	 Pembrolizumab^{J,10} (if MSI-H, dMMR or TMB-H [≥10 mut/Mb]) Nivolumab + ipilimumab^e (if MSI-H or dMMR, for intestinal type only) Larotrectinib (if <i>NTRK</i> gene fusion positive) Entrectinib (if <i>NTRK</i> gene fusion positive)

Chemoradiation

Preferred Regimens: (Pancreatobiliary, Mixed, and Intestinal Types)

Other Recommended Regimens: (Pancreatobiliary only)

• Capecitabine + concurrent RT • 5-FU + concurrent RT

Gemcitabine + concurrent RT¹⁶

Taipei VGH Practice
Guidelines:
Oncology Guidelines Index

National Comprehensive Cancer Network®

ive NCCN Guidelines Version 1.2022 Ampullary Adenocarcinoma

Subsequent Therapy for Disease Progression

	Pancreatobiliary/Mixed Type		Intestinal Type	Useful in Certain Circumstances
Good PS ^f	If prior gemcitabine based therapy: • 5-FU + leucovorin + liposomal irinotecan ¹¹ • 5-FU + leucovorin + irinotecan (FOLFIRI) ¹²⁻¹⁵ • FOLFIRINOX ^a or modified FOLFIRINOX ^{a,g,7} • Oxaliplatin + 5-FU + leucovorin (OFF) ¹⁴ • FOLFOX • CapeOx • CapeOx • 5-FU + leucovorin	If prior fluoropyrimidine based therapy: • Gemcitabine • Gemcitabine + albumin-bound paclitaxel • Gemcitabine + capecitabine • FOLFIRI or 5-FU + leucovorin + liposomal irinotecan (if no prior irinotecan) If prior oxaliplatin therapy: • FOLFIRI or 5-FU + leucovorin + liposomal irinotecan (if no prior irinotecan)	If prior oxaliplatin-based therapy: • FOLFIRI ± bevacizumab ^h	 Pembrolizumab^{e,10} (if MSI-H, dMMR or TMB-H [≥10 mut/Mb]) Dostarlimab-gxly^{ê,k,9} (if MSI-H or dMMR) Nivolumab + ipilimumab^e (if MSI-H or dMMR) Larotrectinib (if <i>NTRK</i> gene fusion positive) Entrectinib (if <i>NTRK</i> gene fusion positive) Gemcitabine + cisplatin⁵ (only for known <i>BRCA1/2</i> mutations)
Poor PS	 Gemcitabine Capecitabine (category 2B) 5-FU + leucovorin (category For select patients with ECOC regimensⁱ: FOLFOX CapeOX FOLFIRI Gemcitabine + albumin-bour 	G 2 consider multi-agent	 5-FU + leucovorin For select patients with ECOG 2 consider multi-agent regimens¹: Capecitabine ± bevacizumab^h 5-FU ± bevacizumab^h FOLFOX ± bevacizumab^h FOLFIRI ± bevacizumab^h FOLFOXIRI ± bevacizumab^h CapeOx ± bevacizumab^h 	 Pembrolizumab^e (if MSI-H, dMMR or TMB-H [≥10 mut/Mb]) Dostarlimab-gxly^{e,k,9} (if MSI-H or dMMR) Nivolumab + ipilimumab^e (if MSI-H or dMMR) Larotrectinib (if <i>NTRK</i> gene fusion positive) Entrectinib (if <i>NTRK</i> gene fusion positive)

Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-1281.

Taipei VGH Practice
Guidelines:
Oncology Guidelines Index

Recommended treatment of Ampullary adenocarcinoma

- Ampullary cancer patients with <u>T2 or above</u> stage or lymph nodepositive tumors are associated with increased recurrence risk and therefore, could be benefitted from adjuvant treatment. A common strategy in the United States is adjuvant chemotherapy with gemcitabine plus capecitabine or <u>fluoropyrimidine</u> for <u>6 months</u> if systemic therapy alone is chosen and excellent performance status.
- For most patients with resected ampullary cancer stage T2N0 or higher, the addition of concurrent infusional FU-based chemoradiotherapy to adjuvant chemotherapy was usually suggested in the United States.
- The commonly used dose is 50.4 grays given in 4 to 6 weeks concurrently with fluoropyrimidine or gemcitabine-based treatment in adjuvant setting either sandwiched between chemotherapy or after 4 to 5 months of chemotherapy.

Taipei VGH Practice
Guidelines:
Oncology Guidelines Index

Recommended regimens of Periampullary adenocarcinoma

- FOLFOX: Oxaliplatin 85 mg/m² iv, leucovorin, 400 mg/m²; Fluorouracil, Fluorouracil, 400 mg/m², then 1200 mg/m² for 2 days, repeat every 2 weeks
- FOLFIRI: Irinotecan 180 mg/m² iv, leucovorin, 400 mg/m²; Fluorouracil, Fluorouracil, 400 mg/m², then 1200 mg/m² for 2 days, repeat every 2 weeks
- FL: Fluorouracil, 2200 mg/m² and leucovorin, 150 mg/m²; given as a 24-hour continuous infusion, every 2 weeks
- Gemcitabine at 1000 mg/m² over 30 minutes, weekly for 3 weeks every 28 days ± oxaliplatin 85 mg/m² iv for 2 hours
- **GEMOX**: Gemcitabine at 1000 mg/m² over 30 minutes , weekly for 7 weeks and rest 1 week, then weekly for 3 weeks every 28 days \pm oxaliplatin 85 mg/m² iv for 2 hours
- EEPFL: Epirubicin, 10 mg/m²; etoposide, 50 mg/m²; cisplatin, 20 mg/m²; leucovorin, 150 mg/m²; and fluorouracil, 2200 mg/m² given as a 24-hour continuous infusion, every 2 weeks
- PFL: Cisplatin, 20 mg/m²; leucovorin, 150 mg/m²; and fluorouracil, 2200 mg/m² given as a 24-hour continuous infusion, every 2 weeks
- **CAPEOX**: Capecitabine 1000 mg/m² PO bid for 10 days and \pm oxaliplatin 85 mg/m² iv for 2 hours every 14 days
- TS-1 orally twice daily at a dose according to the body surface area (BSA) (< 1.25 m², 80 mg/d; \geq 1.25 to < 1.5 m², 100 mg/d; \geq 1.5 m², 120 mg/d) on days 1 through 28 of a 42-day cycle 25

Version 2022.11.03 Table of Content Staging, Manuscript

Recommended Immunotherapy of Periampullary adenocarcinoma

For dMMR/MSI-H only

Pembrolizumab

Pembrolizumab 2 mg/kg IV every 3 weeks, or Pembrolizumab 200 mg IV every 3 weeks, or Pembrolizumab 400 mg IV every 6 weeks

Nivolumab

Nivolumab 3 mg/kg every 2 weeks, or Nivolumab 240 mg IV every 2 weeks, or Nivolumab 480 mg IV every 4 weeks

• Ipilimumab + nivolumab

Nivolumab 3 mg/kg (30-minute IV infusion) Ipilimumab 1 mg/kg (30-minute IV infusion) Once every 3 weeks for four doses, then Nivolumab 3 mg/kg IV or nivolumab 240 mg IV every 2 weeks

N Engl J Med 2020; 383:2207-2218(KEYNOTE-177)

Lancet Oncol 2017; 18: 1182–91(CHECKMATE-142)

Journal of Clinical Oncology 2018 36:8, 773-779(CHECKMATE-142)

References

- 1. Coit DG, et al. AJCC cancer staging manual. 8 ed. New York: Springer; 2017.
- 2. Al B. Benson III, et al. NCCN Clinical Practice Guidelines in Oncology version 1.2022: Small bowel adenocarcinoma, September 03, 2021.
- 3. Neoptolemos, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11;308(2):147-56.
- 4. Tsai PJ, et al. Diagnostic and therapeutic dilemmas in periampullary lesions. Hepatogastroenterology. 2012 Jul-Aug;59(117):1621-5.
- 5. Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372:2509-2520.
- 6. Regalla DKR, et al. Therapeutic options for ampullary carcinomas. Oncol Rev. 2019 Sep 10;13(2):440.
- 7. Nassour I, et al. Association of Adjuvant Therapy with Improved Survival in Ampullary Cancer: A National Cohort Study. J Gastrointest Surg. 2018 Apr;22(4):695-702.
- 8. Li HB, et al. Prognostic Nomogram for Disease-Specific Survival in Patients with Non-metastatic Ampullary Carcinoma After Surgery. Ann Surg Oncol. 2019 Apr;26(4):1079-1085.

Taipei VGH Practice
Guidelines:
Oncology Guidelines Index

- Overman MJ, et al, Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018 Mar 10;36(8):773-779
- 10. Chang DK,et al. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol. 2013 Apr 1;31(10):1348-1356
- 11. Bolm L, et al, Adjuvant therapy is associated with improved overall survival in patients with pancreatobiliary or mixed subtype ampullary cancer after pancreatoduodenectomy - A multicenter cohort study. Pancreatology. 2020 Apr;20(3):433-441
- 12. Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372:2509-2520.
- Onkendi EO, et, al. 15-year experience with surgical treatment of duodenal carcinoma: a comparison of periampullary and extra-ampullary duodenal carcinomas. J Gastrointest Surg. 2012 Apr;16(4):682-91
- 14. Vo NP, et al.. Efficacy and safety of adjuvant therapy after curative surgery for ampullary carcinoma: A systematic review and meta-analysis. Surgery. 2021 Oct;170(4):1205-1214.

Taipei VGH Practice
Guidelines:
Oncology Guidelines Index

- 15. Moekotte AL, Lof S, Van Roessel S, et al. Histopathologic Predictors of Survival and Recurrence in Resected Ampullary Adenocarcinoma. Ann Surg 2020;272:1086-1093.
- Yoo YJ, Kang CM, Choi M, Rho SY, Preoperative prognostic nutritional index as an independent prognostic factor for resected ampulla of Vater cancer. PLoS One. 2020 Mar 3;15(3):e0229597
- Litjens G, van Laarhoven CJHM, Prokop M, van Geenen EJM, Hermans JJ. Routine contrast-enhanced CT is insufficient for TNM-staging of duodenal adenocarcinoma. Abdom Radiol (NY). 2022 Oct;47(10):3436-3445.
- Amano T, Iijima H, Shinzaki S, Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma. BMC Cancer. 2021 Aug 31;21(1):978.
- 19. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-1281
- Kaslow SR, Prendergast K, Vitiello GA, Hani L, Berman RS, Lee AY, Correa-Gallego C. Systemic therapy for duodenal adenocarcinoma: An analysis of the National Cancer Database (NCDB). Surgery. 2022 Jul;172(1):358-364.

Taipei VGH Practice
Guidelines:
Oncology Guidelines Index

- 21. O'Reilly EM, Lee JW, Zalupski Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline *BRCA/PALB2* Mutation. J Clin Oncol. 2020 May 1;38(13):1378-1388
- Lohse, I., Borgida, A., Cao, P. *et al.* BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. *Br J Cancer* 113, 425– 432 (2015).